Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most claims are non-label, non-FDA-label topics (e.g., legality of online purchase, pharmacy practices, red flags, branding/generic availability). The only drug-label-aligned elements are that tenapanor can cause diarrhea and that diarrhea can be associated with dehydration/electrolyte abnormalities (hyponatremia). Several label-specific aspects (indication, dosing/timing) are inaccurate or irrelevant to the claims evaluated.
Category Scores
Accurate Statements
Tenapanor can cause diarrhea.
Warnings/Precautions 5.1 and Adverse Reactions 6.1 describe diarrhea as the most common adverse reaction.
The diarrhea caused by tenapanor can be significant enough to affect hydration and electrolytes in some people.
Warnings/Precautions 5.1 states diarrhea is associated with dehydration and hyponatremia (electrolyte abnormality) in less than 1% of patients.
Unsupported Statements
Tenapanor is a prescription medicine in many countries.
No such regulatory/market availability statement is present in the provided FDA label excerpts.
Tenapanor is marketed as Tenapanor for IBS-C.
The label excerpt provided (XPHOZAH) indicates use for reducing serum phosphorus in adults with CKD on dialysis, not IBS-C.
In many countries, you typically cannot legally buy tenapanor hydrochloride online from an ordinary website without a licensed pharmacy and a valid prescription.
No information about legality of online purchasing, pharmacy licensing, or prescription requirements appears in the provided label excerpts.
Buying tenapanor hydrochloride from unregulated sellers raises risks like counterfeit or incorrect dosing.
No counterfeit/incorrect dosing from unregulated sellers or related consumer-safety language is present in the provided label excerpts.
The safest way to obtain tenapanor for IBS-C is to have a clinician confirm you qualify for tenapanor based on your diagnosis and medical history.
Label excerpts provided do not address IBS-C or general advice about obtaining medicine; they provide specific contraindications/administration/dosing for the indicated population.
Tenapanor is sold under brand names.
The provided label excerpt does not support generalized statements about branding in all markets.
Tenapanor is sometimes sold as a generic where approved.
No information about generic availability by jurisdiction is present in the provided label excerpts.
Red flags for online listings include selling without requiring a prescription where one is needed.
No label information addresses red flags for online listings or prescription/dispensing practices.
Red flags for online listings include refusing to provide pharmacy licensing details.
No label information addresses pharmacy licensing details or online seller screening.
Red flags for online listings include unrealistically low prices or 'no prescription required'.
No label information addresses pricing, online listing red flags, or prescription requirements.
Red flags for online listings include vague product labeling or inconsistent tablet strength.
No label information addresses online listing red flags.
If a listing doesn’t match the packaging/strength sold by licensed channels in the country, it is high risk.
No such consumer guidance is included in the provided label excerpts.
A licensed pharmacy will usually ask for your prescription (or prescriber authorization).
No label information addresses pharmacy workflow or patient intake practices.
A licensed pharmacy will usually ask for your dosing strength as written on the prescription.
No label information addresses pharmacy intake questions.
A licensed pharmacy will usually ask for patient information including age.
No label information addresses pharmacy intake questions about age.
A licensed pharmacy will usually ask for patient information including other medications.
No label information addresses pharmacy intake questions; while drug interactions exist, the claim is about pharmacy behavior.
A licensed pharmacy will usually ask for patient information including kidney-related issues if applicable.
No label information addresses pharmacy intake behavior.
Tenapanor hydrochloride is the chemical form of the drug.
The provided label excerpt does not explicitly state that tenapanor hydrochloride is the chemical form of the drug in this way.
In practice, what matters is the approved medicine product in the region (brand or generic name), tablet strength, and that it is dispensed by a licensed pharmacy with correct labeling.
The provided label excerpts do not contain guidance about regional brand/generic selection or dispensing conditions.
Contradictions
High
AI Statement
Tenapanor is marketed as Tenapanor for IBS-C.
Label Reference
Indications and Usage (1): XPHOZAH is indicated to reduce serum phosphorus in adults with CKD on dialysis (add-on therapy), not IBS-C.
Important Omissions
FDA label indication and required patient population (reduce serum phosphorus in adults with CKD on dialysis; inadequate response to phosphate binders or intolerance).
Importance:
High
Label-specific contraindications (mechanical GI obstruction; contraindicated in patients <6 years).
Importance:
Moderate
Label-specific administration timing (before morning/evening meals; not right before hemodialysis; dosing adjustment for GI tolerability; missed dose instructions).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Main safety risk arises from an apparent indication mismatch (IBS-C vs CKD on dialysis) plus lack of label-required contraindications/administration details. Diarrhea statements are broadly consistent with the label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Incorrect indication/market positioning (IBS-C) and substantial inclusion of non-label claims about purchase legality/red flags and pharmacy practices.
Suggested Improvement
Restrict claims to FDA label-supported information (XPHOZAH/XPHOZAH-tenapanor indication for CKD on dialysis phosphate reduction, label dosing/admin timing, contraindications, and diarrhea/dehydration/hyponatremia association). Remove jurisdictional/legal/consumer red-flag and pharmacy-procedure assertions not present in the label.